HIV-HBV coinfection in Southern Africa and the effect of Lamivudine- Versus tenofovir-containing cART on HBV outcomes

Journal of Acquired Immune Deficiency Syndromes

Volumn 64, Issue 2, 2013, Pages 174-182

  Hamers, Raph L ^a,b,c   Zaaijer, Hans L ^a,d   Wallis, Carole L ^e,f   Siwale, Margaret ^g   Ive, Prudence ^e   Botes, Mariette E ^h   Sigaloff, Kim C E ^a,b,c   Hoepelman, Andy I M ⁱ   Stevens, Wendy S ^e   Rinke De Wit, Tobias F ^a,b,c  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b PharmAccess Foundation   (Netherlands)

^c AMSTERDAM INSTITUTE FOR GLOBAL HEALTH AND DEVELOPMENT   (Netherlands)

^d Department of Blood Borne Infections ^*  (Netherlands)

^e UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^f LANCET LABORATORIES   (South Africa)

^g Lusaka Trust Hospital   (Zambia)

^h Muelmed Hospital   (South Africa)

ⁱ UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Antiretroviral therapy; Hepatitis B virus; HIV; Sub Saharan Africa; Viral drug resistance

Indexed keywords

ABACAVIR; EFAVIRENZ; EMTRICITABINE; ENTECAVIR; HEPATITIS B SURFACE ANTIGEN; LAMIVUDINE; NEVIRAPINE; STAVUDINE; TELBIVUDINE; TENOFOVIR; VIRUS DNA; ZIDOVUDINE;

ADULT; AFRICA; ARTICLE; CD4 LYMPHOCYTE COUNT; FEMALE; FOLLOW UP; GENOTYPE; HEPATITIS B; HEPATITIS B VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIMIT OF DETECTION; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; MULTICENTER STUDY; MUTATION; OUTCOME ASSESSMENT; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; ZAMBIA;

ADENINE; ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; COHORT STUDIES; COINFECTION; DNA, VIRAL; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HIV INFECTIONS; HIV-1; HUMANS; LAMIVUDINE; MALE; MIDDLE AGED; MUTATION; ORGANOPHOSPHONATES; PROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE INHIBITORS; SOUTH AFRICA; TREATMENT OUTCOME; ZAMBIA;

EID: 84885295369     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0b013e3182a60f7d     Document Type: Article

References (48)

1. Bor J, Herbst AJ, Newell ML, et al. Increases in adult life expectancy in rural South Africa: valuing the scale-up of HIV treatment. Science. 2013; 339: 961-965.
2. Barth RE, Huijgen Q, Taljaard J, et al. Hepatitis B/C and HIV in sub- Saharan Africa: an association between highly prevalent infectious diseases. A systematic review and meta-analysis. Int J Infect Dis. 2010;14: e1024-e1031.
3. Weber R, Sabin CA, Friis-Moller N, et al. Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch Intern Med. 2006;166: 1632-1641.
4. Nikolopoulos GK, Paraskevis D, Hatzitheodorou E, et al. Impact of hepatitis B virus infection on the progression of AIDS and mortality in HIV-infected individuals: a cohort study and meta-analysis. Clin Infect Dis. 2009;48: 1763-1771.
5. Hoffmann CJ, Seaberg EC, Young S, et al. Hepatitis B and long-term HIV outcomes in coinfected HAART recipients. AIDS. 2009;23: 1881-1889.
6. Liaw YF, Sung JJ, Chow WC, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med. 2004; 351: 1521-1531.
7. Lok AS, Lai CL, Leung N, et al. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology. 2003;125: 1714-1722.
8. Matthews GV, Avihingsanon A, Lewin SR, et al. A randomized trial of combination hepatitis B therapy in HIV/HBV coinfected antiretroviral naive individuals in Thailand. Hepatology. 2008;48: 1062-1069.
9. Benhamou Y, Fleury H, Trimoulet P, et al. Anti-hepatitis B virus efficacy of tenofovir disoproxil fumarate in HIV-infected patients. Hepatology. 2006;43: 548-555.
10. Avihingsanon A, Lewin SR, Kerr S, et al. Efficacy of tenofovir disoproxil fumarate/emtricitabine compared with emtricitabine alone in antiretroviral-naive HIV-HBV coinfection in Thailand. Antivir Ther. 2010; 15: 917-922.
11. Castellares C, Barreiro P, Martin-Carbonero L, et al. Liver cirrhosis in HIV-infected patients: prevalence, aetiology and clinical outcome. J Viral Hepat. 2008;15: 165-172.
12. Galluzzo C, Liotta G, Andreotti M, et al. Emergence of lamivudine resistance hepatitis B virus mutations in pregnant women infected with HBV and HIV receiving antiretroviral prophylaxis for the prevention of mother-to-infant transmission in Malawi. J Med Virol. 2012;84: 1553-1557.
13. Kim HN, Scott J, Cent A, et al. HBV lamivudine resistance among hepatitis B and HIV coinfected patients starting lamivudine, stavudine and nevirapine in Kenya. J Viral Hepat. 2011;18:e447-e452.
14. Matthews GV, Manzini P, Hu Z, et al. Impact of lamivudine on HIV and hepatitis B virus-related outcomes in HIV/hepatitis B virus individuals in a randomized clinical trial of antiretroviral therapy in southern Africa. AIDS. 2011;25: 1727-1735.
15. Barth RE, Huijgen Q, Tempelman HA, et al. Presence of occult HBV, but near absence of active HBV and HCV infections in people infected with HIV in rural South Africa. J Med Virol. 2011;83: 929-934.
16. Mphahlele MJ, Lukhwareni A, Burnett RJ, et al. High risk of occult hepatitis B virus infection in HIV-positive patients from South Africa. J Clin Virol. 2006;35: 14-20.
17. Lukhwareni A, Burnett RJ, Selabe SG, et al. Increased detection of HBV DNA in HBsAg-positive and HBsAg-negative South African HIV/AIDS patients enrolling for highly active antiretroviral therapy at a Tertiary Hospital. J Med Virol. 2009;81: 406-412.
18. Firnhaber C, Viana R, Reyneke A, et al. Occult hepatitis B virus infection in patients with isolated core antibody and HIV co-infection in an urban clinic in Johannesburg, South Africa. Int J Infect Dis. 2009;13: 488-492.
19. Hamers RL, Oyomopito R, Kityo C, et al. Cohort profile: the PharmAccess African (PASER-M) and the TREAT Asia (TASER-M) Monitoring Studies to Evaluate Resistance - HIV drug resistance in sub-Saharan Africa and the Asia-Pacific. Int J Epidemiol. 2012;41(1): 43-54.
20. Hamers RL, Schuurman R, Sigaloff KC, et al. Effect of pretreatment HIV-1 drug resistance on immunological, virological, and drug-resistance outcomes of first-line antiretroviral treatment in sub-Saharan Africa: a multicentre cohort study. Lancet Infect Dis. 2012;12: 307-317.
21. Hamers RL, Sigaloff KCE, Wensing AM, et al. Patterns of HIV-1 drugresistance after first-line ART failure in six sub-Saharan African countries: implications for second-line ART strategies. Clin Infect Dis. 2012; 54: 1660-1669.
22. Ministry of Health Zambia. Antiretroviral Therapy for Chronic HIV Infection in Adults and Adolescents. New ART Protocols. Lusaka, Zambia: Ministry of Health; 2007.
23. Republic of South Africa, National Department of Health. National Antiretroviral Treatment Guidelines, 2004. Jacana; 2004.
24. Zaaijer HL, Bouter S, Boot HJ. Substitution rate of the hepatitis B virus surface gene. J Viral Hepat. 2008;15: 239-245.
25. Snow-Lampart A, Chappell B, Curtis M, et al. No resistance to tenofovir disoproxil fumarate detected after up to 144 weeks of therapy in patients monoinfected with chronic hepatitis B virus. Hepatology. 2011;53: 763-773.
26. World Health Organization. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach, 2010 revision. Available at: http://whqlibdoc.who.int/publications/2010/ 9789241599764-eng.pdf. Geneva, 2010. Accessed July 1, 2011.
27. Hoffmann CJ, Charalambous S, Martin DJ, et al. Hepatitis B virus infection and response to antiretroviral therapy (ART) in a South African ART program. Clin Infect Dis. 2008;47: 1479-1485.
28. Andreone P, Gramenzi A, Cursaro C, et al. High risk of hepatocellular carcinoma in anti-HBe positive liver cirrhosis patients developing lamivudine resistance. J Viral Hepat. 2004;11: 439-442.
29. Sheldon J, Camino N, Rodes B, et al. Selection of hepatitis B virus polymerase mutations in HIV-coinfected patients treated with tenofovir. Antivir Ther. 2005;10: 727-734.
30. Delaney WE, Ray AS, Yang H, et al. Intracellular metabolism and in vitro activity of tenofovir against hepatitis B virus. Antimicrob Agents Chemother. 2006;50: 2471-2477.
31. Piroth L, Carrat F, Larrat S, et al. Prevalence and impact of GBV-C, SEN-V and HBV occult infections in HIV-HCV co-infected patients on HCV therapy. J Hepatol. 2008;49: 892-898.
32. Nunez M, Ramos B, Diaz-Pollan B, et al. Virological outcome of chronic hepatitis B virus infection in HIV-coinfected patients receiving anti-HBV active antiretroviral therapy. AIDS Res Hum Retroviruses. 2006;22: 842-848.
33. de Vries-Sluijs TE, Reijnders JG, Hansen BE, et al. Long-term therapy with tenofovir is effective for patients co-infected with human immunodeficiency virus and hepatitis B virus. Gastroenterology. 2010;139: 1934-1941.
34. Sheng WH, Kao JH, Chen PJ, et al. Evolution of hepatitis B serological markers in HIV-infected patients receiving highly active antiretroviral therapy. Clin Infect Dis. 2007;45: 1221-1229.
35. De Luca A, Bugarini R, Lepri AC, et al. Coinfection with hepatitis viruses and outcome of initial antiretroviral regimens in previously naive HIV-infected subjects. Arch Intern Med. 2002;162: 2125-2132.
36. Konopnicki D, Mocroft A, de Wit S, et al. Hepatitis B and HIV: prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort. AIDS. 2005; 19: 593-601.
37. Law WP, Duncombe CJ, Mahanontharit A, et al. Impact of viral hepatitis co-infection on response to antiretroviral therapy and HIV disease progression in the HIV-NAT cohort. AIDS. 2004;18: 1169-1177.
38. Idoko J, Meloni S, Muazu M, et al. Impact of hepatitis B virus infection on human immunodeficiency virus response to antiretroviral therapy in Nigeria. Clin Infect Dis. 2009;49: 1268-1273.
39. Rouet F, Chaix ML, Inwoley A, et al. HBV and HCV prevalence and viraemia in HIV-positive and HIV-negative pregnant women in Abidjan, Cote d'Ivoire: the ANRS 1236 study. J Med Virol. 2004;74: 34-40.
40. de Lalla F, Rizzardini G, Rinaldi E, et al, HBV, delta-agent and Treponema pallidum infections in two rural African areas. Trans R Soc Trop Med Hyg. 1990;84: 144-147.
41. Shao JF, Haukenes G, Yangi E, et al. Association of hepatitis B and human immunodeficiency virus infections in Tanzanian population groups. Eur J Clin Microbiol Infect Dis. 1993;12: 62-64.
42. N'Dri-Yoman T, Anglaret X, Messou E, et al. Occult HBV infection in untreated HIV-infected adults in Cote d'Ivoire. Antivir Ther. 2010;15: 1029-1034.
43. Pogany K, Zaaijer HL, Prins JM, et al. Occult hepatitis B virus infection before and 1 year after start of HAART in HIV type 1-positive patients. AIDS Res Hum Retroviruses. 2005;21: 922-926.
44. Kao JH, Chen PJ, Lai MY, et al. Hepatitis B genotypes correlate with clinical outcomes in patients with chronic hepatitis B. Gastroenterology. 2000;118: 554-559.
45. Kramvis A, Kew MC. Relationship of genotypes of hepatitis B virus to mutations, disease progression and response to antiviral therapy. J Viral Hepat. 2005;12: 456-464.
46. Kew MC, Kramvis A, Yu MC, et al. Increased hepatocarcinogenic potential of hepatitis B virus genotype A in Bantu-speaking sub-Saharan Africans. J Med Virol. 2005;75: 513-521.
47. World Health Organization and Joint United Nations Programme on HIV/AIDS. Global HIV/AIDS response: epidemic update and health sector progress towards universal access: progress report 2011. Available at: http://www.who.int/hiv/ pub/progress-report2011/hiv-full-report-2011.pdf. Accessed July 1, 2011.
48. Sagnelli E, Coppola N, Scolastico C, et al. Virologic and clinical expressions of reciprocal inhibitory effect of hepatitis B, C, and delta viruses in patients with chronic hepatitis. Hepatology. 2000;32: 1106-1110.